• Danaher has completed its acquisition of Masimo (NasdaqGS:MASI), which will now operate as a standalone subsidiary.
• Masimo is being integrated into Danaher’s Diagnostics segment, and its shares have been delisted from Nasdaq.
• The transaction ends Masimo’s run as an independent public company and introduces a new leadership structure under Danaher.

For readers who have followed NasdaqGS:MASI as a patient monitoring and healthcare technology stock, this deal reshapes how you think about the business. Masimo’s products sit at the intersection of hospital diagnostics, monitoring hardware, and software enabled decision support, a space where large scale platforms and distribution matter. Being housed within Danaher’s Diagnostics segment places those technologies alongside a broader test and measurement portfolio that already serves hospitals and labs.

With Masimo now delisted, existing shareholders move from a standalone equity story to exposure embedded within Danaher. Key factors to follow from here include how Masimo’s products are positioned inside the Diagnostics segment, how leadership aligns priorities, and how any integration decisions might affect product roadmaps and customer relationships over time.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

The completed US$9.5b cash acquisition closes the chapter on Masimo as an independently traded stock and folds its patient monitoring portfolio into a much larger healthcare platform alongside players like Thermo Fisher and Becton Dickinson. For former Masimo shareholders, the value is now locked in at the US$180 per share deal price, with any future upside or downside from Masimo’s operations reflected inside Danaher. The extensive index removals and closure or withdrawal of Masimo’s historical shelf registrations are mechanical outcomes of the delisting rather than fresh signals about business performance. More meaningful for the future of the business is the clean sweep of Masimo’s board and senior executives, with Danaher installing its own governance framework and transition arrangements. That shifts control over capital allocation, product focus, and M&A decisions to Danaher’s leadership, while Masimo operates as an autonomous unit within Diagnostics. Investors who still want exposure to Masimo’s technologies now have to assess Danaher as a whole, including its balance of diagnostics, life sciences, and environmental businesses.

How This Fits Into The Masimo Narrative

• The acquisition places Masimo inside a global diagnostics platform that could support its push into at-home monitoring, telehealth, and broader hospital connectivity that the narrative focuses on.
• At the same time, the replacement of Masimo’s board and senior executives may change priorities around specialty sales expansion and adjacent monitoring markets that the narrative assumes are management led.
• The narrative centres on Masimo as a listed company with its own capital structure, which does not fully factor in outcomes once it is owned by Danaher and no longer priced independently by the market.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Masimo to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ The full board resignations and executive departures could create execution risk if there is any disruption to customer relationships or sales pipelines during the transition into Danaher.
• ⚠️ With Masimo delisted and removed from indices, investors lose direct price transparency on the business, and any Masimo specific risk is now bundled into Danaher’s broader diagnostics and tools portfolio.
• 🎁 Being part of Danaher’s Diagnostics segment may give Masimo access to wider distribution, shared R&D, and larger hospital system relationships than it could reach on its own.
• 🎁 Danaher’s balance sheet and operating model may support longer product cycles and larger scale investments in monitoring hardware, software, and AI enabled decision support that Masimo develops.

What To Watch Going Forward

From here, the key questions sit inside Danaher. Watch how Masimo’s technologies are referenced in Danaher’s diagnostics commentary, what Danaher says about integration versus autonomy, and whether Masimo’s offerings are highlighted as priorities in acute care and remote monitoring. Also pay attention to any updates on leadership roles for Masimo within Danaher, and how the combined company talks about capital spending, R&D focus, and cross selling opportunities into hospital and lab customers.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Masimo, head to the community page for Masimo to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.